Drug metabolism in Sprague-Dawley rat assessed as (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol formation at 50 mg/kg, po after 5 days by HPLC analysis
Drug metabolism in Sprague-Dawley rat assessed as (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)(hydroxy)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol formation at 50 mg/kg, po after 5 days by HPLC analysis
Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 8 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 8 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 4 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 4 hrs relative to dapagliflozin